Tatva Chintan Pharma Chem Ltd (TATVA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Tatva Chintan Pharma Chem Ltd on NSE and BSE, with an AI summary of each filing.
Updated Investor Presentation.
Investor Presentation · 20 Oct 2026, 2:46 am
Tatva Chintan Updates Investor Presentation Following Metric Corrections Tatva Chintan Pharma Chem Limited released an updated investor presentation on 19th Oct'26, rectifying typographical errors on page 12 for H1FY27 metrics: RoE is corrected to 6.3% (previously 2.6%) and annualized Debt-to-EBITDA is adjusted to 1.16x (previously 4.30x). All other financial figures remain unchanged. In Q2FY27, revenue from operations grew 76% YoY (30% QoQ) to ₹2,173 Mn, EBITDA reached ₹407 Mn (up 83% YoY), and PAT surged 116% YoY to ₹215 Mn, despite temporary headwinds from elevated solvent prices and freight costs.
Investor Presentation for the quarter and half year ended 30 September 2026.
Investor Presentation · 19 Oct 2026, 11:37 pm
Tatva Chintan Pharma Chem Reports Strong Q2FY27 Results Tatva Chintan Pharma Chem reported a 76% YoY surge in Q2FY27 revenue from operations to ₹2,173 Mn, while EBITDA (excluding other income) rose 83% YoY to ₹407 Mn with a 19% margin. Q2FY27 PAT surged 116% YoY to ₹215 Mn (EPS of ₹9.17). For H1FY27, revenue reached ₹3,844 Mn (up 60% YoY) and PAT expanded 126% YoY to ₹374 Mn. In Q2FY27, SDA contributed 45% of revenue, driven by EURO 7 emission standard adoption, followed by PASC at 30% and PTC at 21%.
Earnings Call scheduled to be held on Monday, 19 October 2026 at 05:00 p.m. (IST) has been cancelled due to unforeseen circumstances.
Intimation · 19 Oct 2026, 5:00 pm
Tatva Chintan Pharma Chem Cancels Q2 FY27 Earnings Call Tatva Chintan Pharma Chem Limited has cancelled its Earnings Call previously scheduled for 19th Oct'26 at 05:00 p.m. IST due to unforeseen circumstances. The call was originally slated to discuss the company's financial results for the quarter and half-year ended 30th Sep'26, as per regulatory disclosures under SEBI LODR Regulations.
Outcome Of the Board Meeting Held On 19.10.2026
Outcome · 19 Oct 2026, 9:29 pm
Enclosed
Financial Result · 19 Oct 2026, 9:25 pm
Tatva Chintan Pharma Chem Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 19 Oct 2026, 9:22 pm
Tatva Chintan Pharma Chem Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 2,173 (+75.9% YoY | +30.1% QoQ) ■ EBITDA: 407 (+83.2% YoY | +26.0% QoQ) ■ EBITDA Margin (%): 18.7 (+74 bps YoY | -61 bps QoQ) ■ PAT: 215 (+116.3% YoY | +34.2% QoQ) ■ EPS (INR): 9.17 (+116.3% YoY | +34.3% QoQ)
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Intimation · 16 Oct 2026, 10:58 pm
Tatva Chintan Pharma Chem Schedules Investor Meeting with Motilal Oswal Tatva Chintan Pharma Chem Limited announced a one-to-one virtual meeting with Motilal Oswal Investment Advisors Limited scheduled for 26th Oct'26, pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015. The discussions will rely exclusively on publicly available information, and no unpublished price-sensitive information (UPSI) will be shared during the interaction.
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform you that the Earnings Call post announcement of ....
Intimation · 19 Oct 2026, 5:00 pm
Tatva Chintan Schedules Q2FY27 Earnings Conference Call for 19th Oct'26 Tatva Chintan Pharma Chem Limited will host its Q2 & H1FY27 earnings conference call on Monday, 19th Oct'26 at 17:00 hrs IST, following the declaration of its financial results for the period ended 30th Sep'26. The call is hosted by ICICI Securities and will feature senior management representation from Managing Director Chintan Shah and Chief Financial Officer Ajesh Pillai to discuss the company's operational and financial performance.
TATVA CHINTAN PHARMA CHEM LIMITED has informed the Exchange about Board Meeting to be held on 19-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 19 Oct 2026, 5:30 am
Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/10/2026 ,inter alia, to consider and approve and take on record ....
Intimation · 19 Oct 2026, 5:30 am
Tatva Chintan Pharma Chem Schedules Board Meeting for Q2 FY27 Results Tatva Chintan Pharma Chem Limited has scheduled its Board of Directors meeting on 19th Oct'26 to consider, approve, and take on record the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. In compliance with insider trading regulations, the trading window for company insiders remains closed from 1st Oct'26 until 48 hours following the public dissemination of the financial results.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 19 Oct 2026, 5:30 am
Scrutinizer''s Report / Voting Results of 30th Annual General Meeting of the Company held on Friday, 25 September 2026.
Annual General Meeting · 26 Sept 2026, 7:56 pm
Summary of proceedings of the 30th Annual General Meeting held on Friday, 25 September 2026.
Annual General Meeting · 26 Sept 2026, 12:41 am
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Intimation · 17 Sept 2026, 11:52 pm
Tatva Chintan Pharma Chem Schedules Investor Meeting with Ask Investment Managers Tatva Chintan Pharma Chem Limited announced a one-on-one virtual meeting with Ask Investment Managers Limited scheduled for 23rd Sep'26, pursuant to Regulation 30 of SEBI LODR Regulations. The interaction will focus exclusively on publicly available information, and no unpublished price-sensitive information (UPSI) will be discussed.
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Intimation · 08 Sept 2026, 11:55 pm
Tatva Chintan Schedules One-on-One Virtual Investor Meeting with HSBC Securities Tatva Chintan Pharma Chem Limited has announced a one-on-one virtual interaction with HSBC Securities and Capital Pvt. Ltd. scheduled for 15th Sep'26. The management confirmed that discussions will strictly rely on publicly available information, and no unpublished price-sensitive information (UPSI) will be disclosed during the session.
Intimation of Credit Rating
Others (Uncategorized) · 08 Sept 2026, 10:47 pm
CRISIL Upgrades Tatva Chintan Pharma Chem's Credit Ratings CRISIL Ratings upgraded Tatva Chintan Pharma Chem Limited’s credit ratings on 8th Sep'26 across Rs 245 crore total bank loan facilities. Long-term bank facilities were upgraded to CRISIL A-/Stable from CRISIL BBB+/Stable, while short-term facilities were upgraded to CRISIL A2+ from CRISIL A2. The rated debt profile comprises Rs 220 crore in fund-based limits, Rs 10.5 crore in letter of credit and bank guarantees, alongside a Rs 14.5 crore proposed term loan. The upgrade reflects strengthened creditworthiness and improved financial risk metrics.
Intimation of Record Date, Book Closure and Cut-Off Date pursuant to Regulation 42 and 44 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) ....
Others · 27 Aug 2026, 8:34 pm
Tatva Chintan Announces Record Date for FY26 Final Dividend Tatva Chintan Pharma Chem has set Fri, 11 Sep'26 as the record date to determine shareholder eligibility for the FY25-26 final dividend. The 30th AGM will be held on Fri, 25 Sep'26. The Register of Members will be closed from 12 Sep'26 to 25 Sep'26. The cut-off date for e-voting eligibility is Fri, 18 Sep'26. If approved at the AGM, the dividend will be paid on or after 01 Oct'26.
Pursuant to Regulation 34(2)(f) of the SEBI Listing Regulations, we are submitting herewith the Business Responsibility and Sustainability Report (BRSR") for FY 2025-26 which forms part ....
Others (Uncategorized) · 27 Aug 2026, 8:25 pm
Pursuant to Regulation 34(1) of the SEBI Listing Regulations, please find enclosed herewith the Annual Report of the Company along with the Notice of the 30th Annual General Meeting ('AGM') ....
Others (Uncategorized) · 27 Aug 2026, 8:15 pm
Notice of the 30th AGM of the Members of the Company scheduled to be held on Friday, 25 September 2026 at 4:00 p.m. (IST) through Video Conferencing (''VC") / Other Audio Visual Means ("OAVN")
Annual General Meeting · 27 Aug 2026, 7:57 pm
Resignation of a Senior Management Personnel of the Company.
Change in Management · 20 Aug 2026, 12:06 am
Tatva Chintan AVP of R&D Resigns Tatva Chintan Pharma Chem announced the resignation of Mr. Ajay Rawat, Assistant Vice President – Research and Development, a Senior Management Personnel. He submitted his resignation on 14 Aug'26 to pursue external career opportunities. The resignation was accepted by management on 19 Aug'26 and will be effective from the close of business hours on 13 Nov'26. This marks a key leadership change within the company's R&D division.
Communication to Shareholders - Final Dividend for FY 2025-26 - Intimation on Tax Deduction at source (TDS) / withholding tax on Dividend
Dividend · 11 Aug 2026, 10:03 pm
Tatva Chintan Announces FY26 Dividend & Outlines Tax Withholding Requirements Tatva Chintan Pharma Chem has recommended a final dividend of Rs. 2.00 per share (20%) for FY26, pending shareholder approval. Dividend payments are subject to Tax Deducted at Source (TDS). The TDS rate is 10% for residents, but nil if the total dividend is under Rs. 10,000. Non-residents face a 20% withholding tax, plus cess. Higher rates of 20% apply if a shareholder's PAN is invalid or not linked to Aadhaar. Shareholders must submit required tax documents by 10 Sep'26 for applicable lower/nil rates.
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Intimation · 08 Aug 2026, 12:30 am
Tatva Chintan Pharma Chem to Hold Investor Meetings on 12 Aug'26 Tatva Chintan Pharma Chem Limited has scheduled one-to-one virtual meetings with Ambit Global Private Client and TA Associate on 12 Aug'26. The company confirmed that discussions will be based on publicly available information, and no unpublished price-sensitive information (UPSI) will be disclosed. The schedule is subject to potential changes.
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Intimation · 08 Aug 2026, 12:26 am
Tatva Chintan Schedules Investor Meetings on 12 Aug'26 Tatva Chintan Pharma Chem has scheduled virtual one-to-one meetings with Ambit Global Private Client and TA Associate on 12 Aug'26. The company confirmed that discussions will be based on publicly available information and no unpublished price-sensitive information (UPSI) will be disclosed during these interactions. The schedule is subject to potential changes.
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Intimation · 03 Aug 2026, 11:53 pm
Tatva Chintan Schedules Investor Meeting with Mahindra Manulife Tatva Chintan Pharma Chem Ltd has scheduled a virtual one-on-one meeting with Mahindra Manulife Investment Management Private Limited on 06 Aug'26. The company confirmed that discussions will be based on publicly available information, and no unpublished price-sensitive information (UPSI) will be disclosed during the interaction. This engagement is pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements, with meeting details subject to potential change.